Correction to: Scientific Reports https://doi.org/10.1038/s41598-021-97566-z, published online 13 September 2021
The original version of this Article contained an error in the Funding section.
“This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.”
now reads:
“This work was partially funded by the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship F30CA250254 (AL).”
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lauko, A., Kotecha, R., Barnett, A. et al. Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. Sci Rep 12, 1147 (2022). https://doi.org/10.1038/s41598-022-05489-0
Published:
DOI: https://doi.org/10.1038/s41598-022-05489-0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
